C-Sessions

In this powerful session, we have the pleasure of having my friend and fellow cancer patient, Matt Partlow, share his story of where he's come to with treatment and his disease, Multiple Myeloma.  He met with his oncologist, Dr. Lilly of Seattle Cancer Care Alliance this week and mutually decided his treatments have come to an end. Thus, he and his family have made the decision 'Death with Dignity' is his destiny. Please listen in as he shares life and readying himself for the next chapter and experience.  Forever grateful to know him and be able to share his legacy...

On this C-Sessions with Randall Broad an interview with Dr. Jing Zeng,  an Associate Professor in the Department of Radiation Oncology at the  University of Washington School of Medicine.  There are congratulations in order to Dr. Jing Zeng, who officially  became the SCCA Proton Therapy Center's Medical Director on October 16,  after serving as Associate Medical Director since 2019.  Like many, Dr. Zeng was drawn to health care because she wanted to help  people. She studied at Duke University and completed her residency at  Johns Hopkins Hospital focusing on radiation oncology. Although treating  cancer is extremely challenging, Dr. Zeng knew it was her calling.  "It's a privilege that my job is to help people in their time of dire  need. Work doesn't feel like work when you know what you're doing is  meaningful," says Dr. Zeng.  As one of the first physicians to treat at the Center, Dr. Zeng  initially specialized in lung cancer radiation. By 2014, she expanded  her role to lead the genitourinary/prostate cancer program - at one  time, treating nearly half of the Center's prostate cancer patients.

In this weeks C-Sessions, we're pleased to have Dr. Jerry Radich of Fred Hutchinson Cancer Research Center.  Please join in to hear Jerry's cancer research world, his theory of the Darwinian nature of cancer evolution, and its implications for genetic therapy.  

Liszet is the Community Health Educator for  Urban Populations for the Fred Hutch/University of Washington Cancer  Consortium's Office of Community Outreach & Engagement (OCOE).  Originally from Arizona where she got her Bachelor of Science degree in  Family Studies and Human Development from the University of Arizona, her  personal experience led her to pursue a career assisting underserved  populations and access to health care. She began her work at West Side  Head Start serving the El Mirage, AZ community which is the same  community she participated in as a child. In 2013, she moved to Seattle  to obtain her Master's in Social Work with a concentration in Health  Policy and Advocacy. Liszet began her career at Fred Hutch in 2015  working as a bilingual Information Specialist at the nation's only NCI  Cancer Information Service, where she provided callers from all over the  world up-to-date cancer information, clinical trial search, and local  resources. Liszet continues her work in health disparities now in cancer  prevention and survivor-ship as part of the Cancer Consortium's OCOE.  She's had the honor of working with African American communities in  clinical trial information sessions, working with the Mexican Consulate  to provide Spanish Cancer information, and most recently recruiting for a  monoclonal Anti-body study for COVID-19. Liszet hopes to expand her  work in connecting with any under-served communities and working towards  decreasing gaps in health care and cancer information resources.  Michael has spent 25 years in the medical industry bringing disruptive  technology to the patients and systems that treat them. He's worked both  with national and international companies to bring the latest  technology to the patient front line.   Additionally, Michael has worked  with large health systems; University of Washington, Kaiser, Stanford,  and Providence from the commercial vendor side.  Focused on breakthrough  diagnostic test for breast and colorectal cancer, helping identifying  patients in the care gap.  Currently, Michael is with Deciphera  Pharmaceuticals, a rare disease cancer company focusing on (GIST  gastrointestinal stromal tumors).  C-Sessions is a fascinating healthcare-focused program designed to  improve communication and collaboration between patients and their  healthcare provider.  "The ultimate takeaway is to improve outcomes," said Randy, adding, "We  believe that education, transparency, and open dialogue are essential to  providing quality healthcare throughout the patient journey and  treatment process."